Compare Abeona Therapeutics Inc (ABEO) vs TeraWulf Inc (WULF) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

WULF trades at $22.21, up 4.86% with strong analyst support despite bearish technical signals. The company recently secured a transformative $19 billion AI infrastructure deal with Anthropic, shifting focus from Bitcoin mining to long-term contracted revenue. However, fundamentals show significant challenges with negative profit margins (-611.46%) and high valuation ratios (P/S 53.86, P/B 84.25) amid consecutive earnings misses.

The outlook balances substantial AI opportunity against current financial weakness. The 20-year Anthropic contract provides revenue visibility, but execution risks and negative cash flow from operations (-$123M) require careful monitoring. With 100% analyst buy ratings and $32.40 consensus target offering 46% upside, the stock presents high-risk, high-reward potential for investors believing in the AI infrastructure pivot.